Yargesa (miglustat) (Miglustat CAPSULE) 100 mg/1

Yargesa (miglustat) is an FDA-approved oral medication manufactured by Edenbridge Pharmaceuticals for treating rare genetic lysosomal storage disorders. It is indicated for Gaucher Type I Disease and Niemann-Pick Disease Type C (NPC), representing a significant therapeutic option in the orphan drug category for neurology and genetic medicine.

Strength

100 mg/1

Pack Size

1 BLISTER PACK in 1 CARTON (42799-709-15) / 15 CAPSULE in 1 BLISTER PACK

Manufacturer / TM Owner

Edenbridge Pharmaceuticals

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Yargesa is used to treat two rare lysosomal storage disorders: Gaucher Type I Disease and Niemann-Pick Disease Type C (NPC). Gaucher disease results from deficiency of the enzyme glucocerebrosidase, leading to accumulation of glucocerebroside in macrophages and various organs. NPC is a progressive neurodegenerative disorder caused by impaired intracellular lipid trafficking. Yargesa functions as a glucosylceramide synthase inhibitor, reducing the synthesis of glucocerebroside and other glycosphingolipids, thereby slowing disease progression. The drug is indicated for adult patients and certain pediatric populations with these conditions. By decreasing substrate accumulation in lysosomes, Yargesa helps alleviate symptoms including hepatosplenomegaly, neurological manifestations, and disease-related complications. Treatment aims to slow disease progression and improve quality of life in patients with these debilitating genetic conditions.

Side Effects

Common side effects of Yargesa include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain, which occur in a significant proportion of patients. Tremor, headache, and dizziness have been reported. Serious adverse events include peripheral neuropathy, which requires monitoring, and potential immune system effects. Laboratory abnormalities may include elevated liver enzymes and thrombocytopenia. Patients require regular monitoring of peripheral nerve function, liver function tests, and platelet counts. Gastrointestinal symptoms often improve with dose adjustment or concurrent use of antidiarrheal agents. Close clinical supervision and periodic laboratory assessment are essential to detect and manage adverse effects promptly.

Precautions & Warnings

Yargesa is contraindicated in patients with known hypersensitivity to miglustat or any excipients. Caution is advised in patients with renal impairment, as dose adjustment may be necessary based on creatinine clearance. Hepatic impairment requires careful monitoring. Pregnancy is a relative contraindication; miglustat may cause fetal harm and should be avoided in pregnant women. Breastfeeding is not recommended. Pediatric use requires careful consideration and dose adjustment based on body surface area. Patients with peripheral neuropathy history require enhanced monitoring. Concurrent use with certain medications affecting renal function should be evaluated. Regular assessment of renal and hepatic function is recommended before and during treatment.

Avoid Interactions

Yargesa may interact with medications affecting renal clearance, potentially altering miglustat levels. Concurrent use with other neurotoxic agents increases peripheral neuropathy risk. Imiglucerase and other enzyme replacement therapies may have additive effects. Patients should avoid excessive alcohol consumption due to increased gastrointestinal side effect risk. No significant food interactions have been identified, though consistent administration timing is recommended. Healthcare providers should review all concurrent medications for potential interactions before initiating Yargesa therapy.

Frequently Asked Questions

Yargesa (miglustat) is used to treat Gaucher Type I Disease and Niemann-Pick Disease Type C (NPC), both rare lysosomal storage disorders. It works by reducing the production of glucocerebroside and other glycosphingolipids that accumulate in these conditions. The medication helps slow disease progression and alleviate symptoms in affected patients.

Yargesa is administered orally as a capsule, typically three times daily. The standard dose is 100 mg per dose, though dosing may be adjusted based on renal function and individual patient tolerance. Patients should take the medication consistently with or without food as directed by their healthcare provider.

Common side effects include diarrhea, nausea, vomiting, abdominal pain, tremor, and headache. Gastrointestinal symptoms are most frequent and often manageable with dose adjustment or antidiarrheal medications. Most side effects are mild to moderate and tend to improve over time with continued treatment.

Yargesa is manufactured by Edenbridge Pharmaceuticals, a pharmaceutical company specializing in rare disease treatments and orphan drug development.

Yes, Yargesa has been designated and approved as an orphan drug by the FDA for both Gaucher Type I Disease and Niemann-Pick Disease Type C. This designation recognizes its use in treating rare diseases affecting small patient populations and provides regulatory incentives for development and commercialization.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.